C
Merck KGaA
MKGAF
$145.36
-$2.55-1.72%
C
Hold
3/6/2025Upgraded
Merck KGaA (MKGAF) was upgraded to C- from D+ on 3/6/2025 due to an increase in the dividend index, valuation index and efficiency index.
Merck KGaA (MKGAF) was upgraded to C- from D+ on 3/6/2025 due to an increase in the dividend index, valuation index and efficiency index.
D
Sell
2/6/2025Downgrade
Merck KGaA (MKGAF) was downgraded to D+ from C- on 2/6/2025 due to a decline in the total return index, volatility index and valuation index.
Merck KGaA (MKGAF) was downgraded to D+ from C- on 2/6/2025 due to a decline in the total return index, volatility index and valuation index.
C
Hold
12/20/2024Downgrade
Merck KGaA (MKGAF) was downgraded to C- from C on 12/20/2024 due to a decline in the total return index and volatility index.
Merck KGaA (MKGAF) was downgraded to C- from C on 12/20/2024 due to a decline in the total return index and volatility index.
C
Hold
11/15/2024Upgraded
Merck KGaA (MKGAF) was upgraded to C from C- on 11/15/2024 due to a major increase in the growth index, valuation index and solvency index. Operating cash flow increased 72.96% from $926.73M to $1.6B, EBIT increased 41.3% from $853.53M to $1.21B, and earnings per share increased from $1.5069 to $2.0448.
Merck KGaA (MKGAF) was upgraded to C from C- on 11/15/2024 due to a major increase in the growth index, valuation index and solvency index. Operating cash flow increased 72.96% from $926.73M to $1.6B, EBIT increased 41.3% from $853.53M to $1.21B, and earnings per share increased from $1.5069 to $2.0448.
C
Hold
9/23/2024Downgrade
Merck KGaA (MKGAF) was downgraded to C- from C on 9/23/2024 due to a decline in the volatility index and valuation index.
Merck KGaA (MKGAF) was downgraded to C- from C on 9/23/2024 due to a decline in the volatility index and valuation index.
C
Hold
8/19/2024Upgraded
Merck KGaA (MKGAF) was upgraded to C from C- on 8/19/2024 due to an increase in the total return index and volatility index.
Merck KGaA (MKGAF) was upgraded to C from C- on 8/19/2024 due to an increase in the total return index and volatility index.
C
Hold
8/2/2024Downgrade
Merck KGaA (MKGAF) was downgraded to C- from C on 8/2/2024 due to a major decline in the growth index, valuation index and efficiency index. Operating cash flow declined 17.52% from $1.12B to $926.73M, EBIT declined 15.55% from $1.01B to $853.53M, and net income declined 13.28% from $753.4M to $653.34M.
Merck KGaA (MKGAF) was downgraded to C- from C on 8/2/2024 due to a major decline in the growth index, valuation index and efficiency index. Operating cash flow declined 17.52% from $1.12B to $926.73M, EBIT declined 15.55% from $1.01B to $853.53M, and net income declined 13.28% from $753.4M to $653.34M.
C
Hold
7/25/2024Upgraded
Merck KGaA (MKGAF) was upgraded to C from C- on 7/25/2024 due to an increase in the volatility index and valuation index.
Merck KGaA (MKGAF) was upgraded to C from C- on 7/25/2024 due to an increase in the volatility index and valuation index.
C
Hold
7/2/2024Downgrade
Merck KGaA (MKGAF) was downgraded to C- from C on 7/2/2024 due to a noticeable decline in the growth index, volatility index and valuation index. Total revenue declined 1.19% from $5.63B to $5.56B, and operating cash flow declined 0.89% from $1.13B to $1.12B.
Merck KGaA (MKGAF) was downgraded to C- from C on 7/2/2024 due to a noticeable decline in the growth index, volatility index and valuation index. Total revenue declined 1.19% from $5.63B to $5.56B, and operating cash flow declined 0.89% from $1.13B to $1.12B.
C
Hold
2/20/2024Upgraded
Merck KGaA (MKGAF) was upgraded to C from C- on 2/20/2024 due to an increase in the volatility index.
Merck KGaA (MKGAF) was upgraded to C from C- on 2/20/2024 due to an increase in the volatility index.
C
Hold
2/5/2024Downgrade
Merck KGaA (MKGAF) was downgraded to C- from C on 2/5/2024 due to a major decline in the total return index, growth index and efficiency index. Total revenue declined 2.44% from $5.77B to $5.63B.
Merck KGaA (MKGAF) was downgraded to C- from C on 2/5/2024 due to a major decline in the total return index, growth index and efficiency index. Total revenue declined 2.44% from $5.77B to $5.63B.
C
Hold
11/16/2016Upgraded
Merck KGaA (MKGAF) was upgraded to C from C- on 11/16/2016 due to a major increase in the growth index, valuation index and efficiency index. Operating cash flow increased 239.06% from $351.3M to $1.19B, net income increased 44.75% from $352.43M to $510.16M, and earnings per share increased from $0.2711 to $0.3907.
Merck KGaA (MKGAF) was upgraded to C from C- on 11/16/2016 due to a major increase in the growth index, valuation index and efficiency index. Operating cash flow increased 239.06% from $351.3M to $1.19B, net income increased 44.75% from $352.43M to $510.16M, and earnings per share increased from $0.2711 to $0.3907.
C
Hold
11/3/2016Downgrade
Merck KGaA (MKGAF) was downgraded to C- from C on 11/3/2016 due to a decline in the volatility index.
Merck KGaA (MKGAF) was downgraded to C- from C on 11/3/2016 due to a decline in the volatility index.
C
Hold
8/26/2016Upgraded
Merck KGaA (MKGAF) was upgraded to C from C- on 8/26/2016 due to a noticeable increase in the total return index, growth index and volatility index. EBIT increased 14.36% from $614.39M to $702.6M, and total revenue increased 6.32% from $4.04B to $4.3B.
Merck KGaA (MKGAF) was upgraded to C from C- on 8/26/2016 due to a noticeable increase in the total return index, growth index and volatility index. EBIT increased 14.36% from $614.39M to $702.6M, and total revenue increased 6.32% from $4.04B to $4.3B.
C
Hold
3/14/2016Upgraded
Merck KGaA (MKGAF) was upgraded to C- from D- on 3/14/2016 due to a significant increase in the efficiency index, growth index and dividend index.
Merck KGaA (MKGAF) was upgraded to C- from D- on 3/14/2016 due to a significant increase in the efficiency index, growth index and dividend index.
D
Sell
3/9/2016Downgrade
Merck KGaA (MKGAF) was downgraded to D- from C on 3/9/2016 due to a significant decline in the efficiency index, growth index and volatility index.
Merck KGaA (MKGAF) was downgraded to D- from C on 3/9/2016 due to a significant decline in the efficiency index, growth index and volatility index.
C
Hold
6/12/2015Downgrade
Merck KGaA (MKGAF) was downgraded to C from B on 6/12/2015 due to a substantial decline in the valuation index and total return index.
Merck KGaA (MKGAF) was downgraded to C from B on 6/12/2015 due to a substantial decline in the valuation index and total return index.
B
Buy
5/22/2015Upgraded
Merck KGaA (MKGAF) was upgraded to B from C on 5/22/2015 due to a significant increase in the growth index, valuation index and volatility index.
Merck KGaA (MKGAF) was upgraded to B from C on 5/22/2015 due to a significant increase in the growth index, valuation index and volatility index.
C
Hold
5/20/2015Downgrade
Merck KGaA (MKGAF) was downgraded to C from B on 5/20/2015 due to a significant decline in the growth index, valuation index and dividend index. Operating cash flow declined 78.02% from $1.43B to $313.37M, and total revenue declined 9.82% from $3.79B to $3.42B.
Merck KGaA (MKGAF) was downgraded to C from B on 5/20/2015 due to a significant decline in the growth index, valuation index and dividend index. Operating cash flow declined 78.02% from $1.43B to $313.37M, and total revenue declined 9.82% from $3.79B to $3.42B.
B
Buy
3/12/2015Upgraded
Merck KGaA (MKGAF) was upgraded to B from C on 3/12/2015 due to a significant increase in the growth index, valuation index and dividend index.
Merck KGaA (MKGAF) was upgraded to B from C on 3/12/2015 due to a significant increase in the growth index, valuation index and dividend index.
C
Hold
3/4/2015Downgrade
Merck KGaA (MKGAF) was downgraded to C from B on 3/4/2015 due to a significant decline in the growth index, valuation index and solvency index. EBIT declined 49.19% from $665.82M to $338.31M, debt to equity increased from 0.37 to 0.5, and total revenue declined 2.5% from $3.89B to $3.79B.
Merck KGaA (MKGAF) was downgraded to C from B on 3/4/2015 due to a significant decline in the growth index, valuation index and solvency index. EBIT declined 49.19% from $665.82M to $338.31M, debt to equity increased from 0.37 to 0.5, and total revenue declined 2.5% from $3.89B to $3.79B.
B
Buy
2/27/2015Upgraded
Merck KGaA (MKGAF) was upgraded to B from B- on 2/27/2015 due to an increase in the volatility index and valuation index.
Merck KGaA (MKGAF) was upgraded to B from B- on 2/27/2015 due to an increase in the volatility index and valuation index.
B
Buy
2/13/2015Upgraded
Merck KGaA (MKGAF) was upgraded to B- from C+ on 2/13/2015 due to an increase in the volatility index and total return index.
Merck KGaA (MKGAF) was upgraded to B- from C+ on 2/13/2015 due to an increase in the volatility index and total return index.
C
Hold
9/11/2014Downgrade
Merck KGaA (MKGAF) was downgraded to C+ from B- on 9/11/2014 due to a large decline in the total return index, volatility index and solvency index. The quick ratio declined from 1.15 to 0.81, and debt to equity increased from 0.33 to 0.36.
Merck KGaA (MKGAF) was downgraded to C+ from B- on 9/11/2014 due to a large decline in the total return index, volatility index and solvency index. The quick ratio declined from 1.15 to 0.81, and debt to equity increased from 0.33 to 0.36.
B
Buy
7/21/2014Downgrade
Merck KGaA (MKGAF) was downgraded to B- from B on 7/21/2014 due to a noticeable decline in the volatility index and total return index.
Merck KGaA (MKGAF) was downgraded to B- from B on 7/21/2014 due to a noticeable decline in the volatility index and total return index.
B
Buy
7/3/2014None
Merck KGaA (MKGAF) was downgraded to B from U on 07/03/2014.
Merck KGaA (MKGAF) was downgraded to B from U on 07/03/2014.
OTC PK
03/07/2025 3:54PM Eastern
Quotes delayed
